Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
525 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02978495 | Neoadjuvant Carboplatin in Triple Negative Breast Cancer | completed | Phase 2 | 154 | Barretos Cancer HospitalOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT02789878 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | completed | Phase 2 | 64 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies(CheckMate 908) | completed | Phase 2 | 166 | Bristol-Myers SquibbINDUSTRY | 15 | Aug 9, 2022 | clinicaltrials |
| NCT04447235 | Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection(TITAN) | terminated | Phase 2 | 77 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04698252 | Local Therapy for ER/PR-positive Oligometastatic Breast Cancer(LARA) | recruiting | Phase 2 | 74 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04424654 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy(PSMA-BAT) | completed | Phase 2 | 20 | Hospital Sirio-LibanesOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05396781 | Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening | completed | Phase 2 | 41 | Anandasabapathy, Sharmila, M.D.INDIV | 2 | Jun 9, 2022 | clinicaltrials |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | withdrawn | Phase 2 | 0 | Janssen Research & Development, LLCINDUSTRY | 11 | May 20, 2022 | clinicaltrials |
| NCT04831567 | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors(MIBNET) | withdrawn | Phase 2 | 0 | AC Camargo Cancer CenterOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05354817 | Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin(Re-Play) | unknown | Phase 2 | 25 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03312868 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | terminated | Phase 2 | 10 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04669132 | Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer(OLNEPA) | completed | Phase 2 | 50 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02857426 | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)(CheckMate 647) | completed | Phase 2 | 66 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 23, 2021 | clinicaltrials |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 13, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
| NCT04622956 | GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide | unknown | Phase 1 / Phase 2 | 47 | University of Sao Paulo General HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT03040791 | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)(ImmunoProst) | unknown | Phase 2 | 38 | Hospital Moinhos de VentoOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04059809 | Photobiomodulation for Breast Cancer Radiodermatitis | completed | Phase 2 / Phase 3 | 48 | AC Camargo Cancer CenterOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT04993014 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer(HER2Cell) | recruiting | Phase 2 | 80 | AC Camargo Cancer CenterOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04741880 | Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial)(ELSA) | unknown | Phase 2 / Phase 3 | 66 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Jul 30, 2021 | clinicaltrials |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 129 | Novartis PharmaceuticalsINDUSTRY | 13 | Jul 28, 2021 | clinicaltrials |
| NCT02867020 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | completed | Phase 2 | 128 | Latin American Cooperative Oncology GroupOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02458638 | A Study of Atezolizumab in Advanced Solid Tumors | completed | Phase 2 | 474 | Hoffmann-La RocheINDUSTRY | 18 | Jun 4, 2021 | clinicaltrials |
| NCT04834089 | Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases(SOROCOV) | unknown | Phase 1 / Phase 2 | 618 | Butantan InstituteOTHER_GOV | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT00606502 | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | completed | Phase 2 | 201 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 5, 2021 | clinicaltrials |
| NCT01783444 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.(BOLERO-6) | completed | Phase 2 | 309 | Novartis PharmaceuticalsINDUSTRY | 18 | Feb 26, 2021 | clinicaltrials |
| NCT03233412 | Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions | completed | Phase 2 | 90 | Barretos Cancer HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01702558 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)(TRAXHER2) | terminated | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 12 | Jan 22, 2021 | clinicaltrials |
| NCT04674696 | Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer(SHORT-ICAR) | unknown | Phase 2 | 54 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Dec 19, 2020 | clinicaltrials |
| NCT03170115 | Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer(ICAR) | terminated | Phase 2 | 25 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03093207 | Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis | completed | Phase 2 / Phase 3 | 34 | Universidade Estadual Paulista Júlio de Mesquita FilhoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02896803 | Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer(PanFLOX) | unknown | Phase 2 | 37 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT03825861 | Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer(FOLFIRINOX) | recruiting | Phase 2 | 27 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT01491737 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer(PERTAIN) | completed | Phase 2 | 258 | Hoffmann-La RocheINDUSTRY | 8 | Oct 28, 2020 | clinicaltrials |
| NCT00542919 | A Study for Patients With Non-Hodgkin's Lymphomas | completed | Phase 2 | 57 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT01915303 | Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease | terminated | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 16 | Sep 18, 2020 | clinicaltrials |
| NCT00967616 | Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy | completed | Phase 2 | 100 | Daiichi SankyoINDUSTRY | 5 | May 4, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY | 17 | Apr 21, 2020 | clinicaltrials |
| NCT00440726 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 31 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 4 | Feb 19, 2020 | clinicaltrials |
| NCT01270373 | NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?(NeoSAMBA) | unknown | Phase 2 | 112 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03834233 | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(CA209-9JC) | unknown | Phase 2 | 24 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT00453388 | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia | completed | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation(IDEALL) | withdrawn | Phase 2 | 0 | TakedaINDUSTRY | 1 | Jan 14, 2020 | clinicaltrials |
| NCT02217566 | Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy | completed | Phase 2 | 46 | Janssen Research & Development, LLCINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials